MYCN and neuroblastoma: Understanding the mechanism of suppression at these genes will have important implications with respect to I-BET726 activity in neuroblastoma, as direct inhibition of these genes could potentially reverse the malignant phenotype of 17q alterations even in the absence of MYCN amplification.